Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: A systematic review and meta-analysis

This meta-analysis of five randomized controlled trials evaluated quadruplet therapy (anti-CD38 mAb plus triplet regimen) versus triplet therapy for transplant-eligible newly diagnosed multiple myeloma (TENDMM). Quadruplet therapy showed a statistically significant improvement in progression-free survival and MRD negativity rate. While overall survival benefit was not significant, the study concluded that quadruplet therapy has a favorable efficacy and safety profile, suggesting its potential as a new standard of care.